Insight Molecular Diagnostics ROE 2014-2025 | IMDX
Current and historical return on equity (ROE) values for Insight Molecular Diagnostics (IMDX) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Insight Molecular Diagnostics ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2025-06-30 | $-0.06B | $0.00B | -2844.44% |
| 2025-03-31 | $-0.06B | $0.01B | -761.29% |
| 2024-12-31 | $-0.06B | $-0.01B | -739.39% |
| 2024-09-30 | $-0.04B | $0.01B | -270.77% |
| 2024-06-30 | $-0.04B | $0.02B | -163.44% |
| 2024-03-31 | $-0.04B | $0.01B | -143.86% |
| 2023-12-31 | $-0.03B | $0.02B | -82.86% |
| 2023-09-30 | $-0.06B | $0.04B | -148.05% |
| 2023-06-30 | $-0.06B | $0.04B | -124.35% |
| 2023-03-31 | $-0.06B | $0.04B | -103.45% |
| 2022-12-31 | $-0.07B | $0.03B | -116.33% |
| 2022-09-30 | $-0.06B | $0.08B | -90.78% |
| 2022-06-30 | $-0.07B | $0.08B | -89.47% |
| 2022-03-31 | $-0.07B | $0.06B | -86.42% |
| 2021-12-31 | $-0.06B | $0.07B | -68.45% |
| 2021-09-30 | $-0.03B | $0.10B | -39.77% |
| 2021-06-30 | $-0.03B | $0.10B | -38.85% |
| 2021-03-31 | $-0.03B | $0.11B | -48.37% |
| 2020-12-31 | $-0.03B | $0.03B | -82.76% |
| 2020-09-30 | $-0.03B | $0.04B | -89.51% |
| 2020-06-30 | $-0.03B | $0.04B | -87.59% |
| 2020-03-31 | $-0.03B | $0.04B | -79.39% |
| 2019-12-31 | $-0.02B | $0.03B | -66.67% |
| 2019-09-30 | $-0.02B | $0.03B | -73.08% |
| 2019-06-30 | $-0.02B | $0.03B | -81.93% |
| 2019-03-31 | $-0.02B | $0.04B | -121.43% |
| 2018-12-31 | $-0.02B | $0.00B | -251.85% |
| 2018-09-30 | $-0.02B | $0.01B | -228.57% |
| 2018-06-30 | $-0.02B | $0.01B | -285.71% |
| 2018-03-31 | $-0.02B | $0.01B | -281.48% |
| 2017-12-31 | $-0.02B | $0.00B | -296.30% |
| 2017-09-30 | $-0.02B | $0.01B | -230.30% |
| 2017-06-30 | $-0.02B | $0.01B | -157.89% |
| 2017-03-31 | $-0.01B | $0.01B | -155.56% |
| 2016-12-31 | $-0.01B | $0.01B | -141.18% |
| 2016-09-30 | $-0.01B | $0.01B | -152.94% |
| 2016-06-30 | $-0.01B | $0.00B | -228.57% |
| 2016-03-31 | $-0.01B | $0.01B | -235.29% |
| 2015-12-31 | $-0.01B | $0.01B | -320.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.076B | $0.002B |
| Insight Molecular Diagnostics Inc. is a pioneering diagnostics technology company. Insight Molecular Diagnostics Inc., formerly known as Oncocyte Corporation, is based in NASHVILLE, Tenn. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $46.099B | 58.65 |
| Tempus AI (TEM) | United States | $13.629B | 0.00 |
| Doximity (DOCS) | United States | $12.349B | 54.94 |
| Hims & Hers Health (HIMS) | United States | $10.193B | 83.52 |
| IRhythm Technologies (IRTC) | United States | $5.074B | 0.00 |
| Hinge Health (HNGE) | United States | $4.605B | 0.00 |
| Privia Health (PRVA) | United States | $2.623B | 194.27 |
| Inspire Medical Systems (INSP) | United States | $2.613B | 38.41 |
| Heartflow (HTFL) | $2.433B | 0.00 | |
| Phreesia (PHR) | United States | $1.732B | 0.00 |
| Enovis (ENOV) | United States | $1.689B | 8.93 |
| 10x Genomics (TXG) | United States | $1.676B | 0.00 |
| Schrodinger (SDGR) | United States | $1.476B | 0.00 |
| Omnicell (OMCL) | United States | $1.452B | 27.97 |
| Azenta (AZTA) | United States | $1.394B | 60.84 |
| Clover Health Investments (CLOV) | United States | $1.338B | 0.00 |
| Claritev (CTEV) | United States | $1.189B | 0.00 |
| Evolent Health (EVH) | United States | $1.059B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.659B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.630B | 0.00 |
| Veradigm (MDRX) | United States | $0.503B | 0.00 |
| Standard BioTools (LAB) | United States | $0.482B | 0.00 |
| Talkspace (TALK) | United States | $0.435B | 130.00 |
| Butterfly Network (BFLY) | United States | $0.363B | 0.00 |
| Carlsmed (CARL) | $0.349B | 0.00 | |
| TruBridge (TBRG) | United States | $0.290B | 50.90 |
| Outset Medical (OM) | United States | $0.243B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.236B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.224B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.211B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.195B | 0.00 |
| CapsoVision (CV) | United States | $0.187B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.141B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.125B | 0.00 |
| American Well (AMWL) | United States | $0.117B | 0.00 |
| CareCloud (CCLD) | United States | $0.115B | 5.23 |
| EUDA Health Holdings (EUDA) | Singapore | $0.098B | 0.00 |
| Pulmonx (LUNG) | United States | $0.065B | 0.00 |
| 111 (YI) | China | $0.062B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.050B | 0.00 |
| HeartBeam (BEAT) | United States | $0.041B | 0.00 |
| Precipio (PRPO) | United States | $0.024B | 0.00 |
| Zhongchao (ZCMD) | China | $0.023B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.019B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.013B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.009B | 0.00 |
| HeartSciences (HSCS) | United States | $0.009B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.007B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.006B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.005B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.004B | 0.00 |
| Movano (MOVE) | United States | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.004B | 0.00 |
| PROFUSA (PFSA) | United States | $0.003B | 0.00 |